Autoantibody	Subtype (percentage with subtype and autoantibody)	Clinical associations
Antinuclear antibody	Limited cutaneous and diffuse cutaneous (95 percent [nucleolar pattern is most specific])	Pulmonary arterial hypertension
		Interstitial lung disease
Anticentromere antibody	Limited cutaneous (60 to 80 percent)	Pulmonary arterial hypertension
	Diffuse cutaneous (2 to 5 percent)	Digital ulcerations or digital loss
Antitopoisomerase-1 antibody (anti-Scl-70)	Diffuse cutaneous (20 to 40 percent)	Rapidly progressive skin thickening
		Scleroderma renal crisis
		Pulmonary fibrosis